Purchase this article with an account.
Byung Yi Ko, Gun-woong Lee, Young-sung Kim, Sung-gook Baek; Inhibition of Corneal Neovascularization by Subconjunctival and Topical Bevacizumab and Sunitinib in an Animal Model. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2387.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effects of subconjunctival injection and topical application of bevacizumab and sunitinib on experimentally induced corneal neovascularization (CNV).
CNV was induced by placing a suture at the right eyes of 36 rabbits. After the suture removal, the rabbits were divided into 6 groups in equal numbers. In group 1, 2, and 3, the right eyes were received the subconjunctival injection of normal saline, bevacizumab (2.5 mg/0.1 mL) and sunitinib (0.25 mg/0.1 mL), respectively, immediately after suture removal and again 1 week later. In group 4, 5, and 6, the right eyes had topical saline, bevacizumab (5 mg/mL) and sunitinib (0.5 mg/mL) bid for 2 weeks, respectively. All of the left eyes received neither treatment and nor suture and served as absolute normal controls. Analysis of CNV was performed by biomicroscopy and histological examination of H&E and CD31 immunohistochemical stain. The extent of phosphorylation of serine threonine kinase (AKT) and extracellular regulated kinase1/2 (ERK1/2) in corneal tissue was analyzed.
On day 14, the mean percentages of CNV area in sunitinib-injected eyes was smaller than the area of saline-injected or bevacizumab-injected eyes (p < 0.01 and p < 0.05, respectively) and in case of topical administration, the mean percentages of CNV area in sunitinib-treated eyes was smaller than the area of saline-treated or bevacizumab-treated eyes (p < 0.001 and p < 0.001, respectively). Sunitinib was more effective in topical application (p < 0.05 at 1 week). In histological examination, sunitinib-treated eyes showed lower vascularity than saline-treated or bevacizumab-treated eyes. In phosphorylation of AKT and ERK1/2 in corneal tissue, both were decreased in bevacizumab and sunitinib-treated group.
These results suggest that sunitinib is more effective than bevacizumab for inhibition of CNV and sunitinib is recommended to be used topically. Further trial needs to be performed.
This PDF is available to Subscribers Only